A Study to Assess the Pharmacokinetics, Safety and Tolerability of Repeat Oral Doses of Darapladib (SB-480848) in Subjects With Severe Renal Impairment

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01711723
First received: October 18, 2012
Last updated: August 29, 2013
Last verified: June 2013
  Purpose

In accordance with the recently revised FDA draft renal impairment guidance (March 2010) which advises the conduct of renal impairment study in drugs that are not predominately eliminated through the renal route, the proposed study will be conducted to formally assess the pharmacokinetics (PK) of darapladib in severely renally impaired subjects.

In this is an open-label, non-randomized study eight subjects with severe renal impairment will be recruited along with 8 healthy control subjects matched to the severe renal impairment subjects based on gender, body mass index (plus or minus 20%) and age (plus or minus 10 years).

All subjects will receive repeat oral doses of darapladib 160 milligram (mg) for 10 consecutive days. The pharmacokinetics of darapladib and its metabolites; and safety and tolerability will be evaluated.

All the subjects will be admitted to the clinic on the evening of Day -1. Subjects may check out of the clinic on Day 2 after all assessments are complete, but must return to the clinic each day (Days 3-8) for dosing and assessments. Subjects will be admitted to the clinic again on the evening of Day 9. After the last dose of the study drug, there will be a follow-up period which will include 2 visits (Day 20-24 and Day 38-52). The total study duration for each subject including the screening, treatment and follow-up periods will be approximately 11 weeks.


Condition Intervention Phase
Atherosclerosis
Drug: Darapladib 160 mg
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of SB-480848 in Healthy Subjects and in Subjects With Severe Renal Impairment

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • AUC (0-τ) for darapladib and as data permit for metabolites M4, M3, and M10 [ Time Frame: On scheduled intervals on Day 10 ] [ Designated as safety issue: No ]
    The PK parameter area under the concentration-time curve over the dosing interval (AUC (0-τ)) will be derived from the plasma concentration-time data.

  • Cmax for darapladib and as data permit for metabolite s M4, M3, and M10 [ Time Frame: On scheduled intervals on Day 10 ] [ Designated as safety issue: No ]
    The PK parameter maximum observed concentration (Cmax) will be derived from the plasma concentration-time data.


Secondary Outcome Measures:
  • Spontaneous AE reporting [ Time Frame: 45days ] [ Designated as safety issue: No ]
    Adverse events (AEs) will be collected from the start of Investigation Product and until the follow-up visit.

  • Clinical laboratory test measurements [ Time Frame: Day-1, Day 11 and post treatment ] [ Designated as safety issue: No ]
    Clinical laboratory tests will include hematology, clinical chemistry and urinalysis.

  • Vital signs measurements [ Time Frame: Day-1, Day1, Day5, Day 11 and post treatment ] [ Designated as safety issue: No ]
    Vital sign measurements will include systolic and diastolic blood pressure and pulse rate. Subjects should have been resting quietly in a supine or semi-supine (recumbent) position for at least 10 minutes prior to taking measurements.

  • Nursing/physician observation [ Time Frame: 20 days ] [ Designated as safety issue: No ]
    The physical examination will include assessments of the skin, lungs, cardiovascular system, and abdomen (liver and spleen).

  • Free fraction (% unbound) of darapladib and its metabolites M3, M4, and M10 (as data permit) [ Time Frame: On scheduled intervals on Day 10 ] [ Designated as safety issue: No ]
    Concentrations of darapladib, M4, M3 and M10 will be determined in plasma samples using the currently approved analytical methodology. Attempts will be made to determine the unbound fraction of darapladib and its metabolites.

  • Tmax and t1/2 of darapladib and its metabolites M3, M4, M3, and M10 (as data permit) [ Time Frame: On scheduled intervals on Day 10 ] [ Designated as safety issue: No ]
    The PK parameters Tmax (time of occurrence of Cmax) and t1/2 (terminal phase half-life) will be derived from the plasma concentration-time data for darapladib and its metabolites M3, M4, M3, and M10.


Enrollment: 16
Study Start Date: October 2012
Study Completion Date: March 2013
Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Renal Impaired Group
Subjects with renal impairment received darapladip 160 mg daily for 10 consecutive days.
Drug: Darapladib 160 mg
Subjects in each group received one tablet orally of Darapladib 160 mg daily for 10 consecutive days. Tablets were taken with food, swallowed whole, not chewed.
Experimental: Healthy Control Group
Healthy volunteers matching with renal impairment subjects for gender, age and BMI; received darapladip 160 mg daily for 10 consecutive days.
Drug: Darapladib 160 mg
Subjects in each group received one tablet orally of Darapladib 160 mg daily for 10 consecutive days. Tablets were taken with food, swallowed whole, not chewed.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • A male or female is eligible to enter and participate in this study if he/she is: A healthy subject with normal renal function: Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. A subject with clinical abnormalities or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator and the GSK Medical Monitor agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures; Estimated Creatinine clearance ≥ 90mL/min calculated by Cockcroft-Gault equation using serum creatinine OR A renally impaired subject - To be classified as renally impaired, subjects must have: An estimated Glomerular Filtration Rate (eGFR) of <30 ml/min /1.73 m2 using the four variable Modification of Diet in Renal Disease (MDRD) equation.
  • Age between 18 and 75 years inclusive, at the time of signing the informed consent.
  • A female subject is eligible to participate if she is of: Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 MlU/ml and estradiol < 40 pg/ml (<140pmol/L) is confirmatory]; Child-bearing potential and agrees to use one of the contraception methods listed in the protocol for an appropriate period of time (as determined by the product label or investigator) prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point. Female subjects must agree to use contraception until the final follow-up visit (35 ± 7 days after last dose of investigational product)
  • Body mass index (BMI) within the range of 19.0-38.0 kg/m2 (inclusive)
  • Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
  • QTcF ≤ 480 msec in all subjects, including those with bundle branch block at screening ECG.

Exclusion Criteria:

Healthy Subjects

  • A positive pre-study drug/alcohol screen.
  • A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody or positive Hepatitis A IGM antibody result within 3 months of screening.
  • A positive test for HIV antibody.
  • Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones
  • History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of >14 drinks for males or >7 drinks for females. One drink is equivalent to 12 g of alcohol: 12 ounces (360 ml) of beer, 5 ounces (150 ml) of wine or 1.5 ounces (45 ml) of 80 proof distilled spirits.
  • The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, or 5 half-lives of the investigational product (whichever is longer).
  • Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
  • Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St. John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
  • Requiring the use of oral or injectable strong CYP3A4 inhibitors (refer to the protocol).
  • Consumption of grapefruit or grapefruit juice > 8oz within 7 days prior to first dose of study medication.
  • Drug abuse within the past 6 months, or current mental condition (psychiatric disorder, senility or dementia), which may affect study compliance or prevent understanding of the aims, investigational procedures or possible consequences of the study.
  • History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
  • History of anaphylaxis, or anaphylactoid (resembling anaphylaxis) reactions (refer to the protocol). History of severe allergic responses.
  • Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
  • Use of oral, injected and implanted hormonal methods of contraception for female subjects.
  • Pregnant females as determined by positive serum hCG test at screening or prior to dosing.
  • Lactating females.
  • Unwillingness or inability to follow the procedures outlined in the protocol.
  • Subjects with a risk of non-compliance in following directions or adhering to study instructions, or any subject that the principal investigator deems unsuitable for participation or continuation.

Renally Impaired Subjects

  • Subjects with a life expectancy less than 3 months.
  • Anticipated need for dialysis during the study.
  • A positive pre-study drug/alcohol screen, except where subject has a prescription for pain or anxiolytic medication that would cause a positive test. Investigator should consult medical monitor with patient history before screening if it is known that a patient could have positive test.
  • Subjects with a positive HIV antibody test.
  • Subjects using any concurrent prohibited medication, and/or receiving concurrent therapy that cannot be safely discontinued and is not approved by the Investigator (see protocol for details on prohibited medications).
  • Cirrhosis, known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones), unstable liver disease (defined by the presence of any of the following felt by the investigator to be related to liver disease and not to other disease processes: ascites, encephalopathy, coagulopathy, hypoalbuminemia, oesophageal or gastric varices, or persistent jaundice), or evidence of abnormal liver function tests (total bilirubin or alkaline phosphatase >1.5 x upper limit of normal [ULN]; or ALT >2.5 x ULN) or other hepatic abnormalities that in the opinion of the investigator would preclude the subject from participation in the study.
  • Severe asthma that is poorly controlled on pharmacotherapy.
  • The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
  • Requiring the use of oral or injectable strong CYP3A4 inhibitors (refer to protocol). Consumption of grapefruit or grapefruit juice within 7 days prior to first dose of study medication
  • If in the opinion of the Investigator there is an unstable cardiovascular, pulmonary, or hepatic condition present, or any other medical condition which the Investigator and the Medical Monitor considers sufficiently serious to interfere with the conduct, completion, or result of this trial or constitutes an unacceptable risk to the subject.
  • History of sensitivity to any of the study medications, or components thereof, or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
  • History of anaphylaxis, or anaphylactoid (resembling anaphylaxis) reactions (refer to the protocol. History of severe allergic responses.
  • Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
  • Use of oral, injected and implanted hormonal methods of contraception for female subjects.
  • Pregnant females as determined by positive serum hCG test at screening or prior to dosing.
  • Lactating females
  • History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of >14 drinks for males or >7 drinks for females. One drink is equivalent to 12 g of alcohol: 12 ounces (360 ml) of beer, 5 ounces (150 ml) of wine or 1.5 ounces (45 ml) of 80 proof distilled spirits.
  • Subjects with a risk of non-compliance in following directions or adhering to study restrictions, or any subject that the principal investigator deems unsuitable for participation or continuation.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01711723

Locations
United States, Florida
GSK Investigational Site
Orlando, Florida, United States, 32809
United States, Minnesota
GSK Investigational Site
Minneapolis, Minnesota, United States, 55404
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT01711723     History of Changes
Other Study ID Numbers: 115676
Study First Received: October 18, 2012
Last Updated: August 29, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by GlaxoSmithKline:
darapladib
Lp-PLA2- inhibitor
healthy volunteer
renal impairment
pharmacokinetics

Additional relevant MeSH terms:
Atherosclerosis
Renal Insufficiency
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Kidney Diseases
Urologic Diseases

ClinicalTrials.gov processed this record on July 24, 2014